Prasad Srinivasan, MD
Allergy & Immunology · Glastonbury, CTNPI 1740253517
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.9% of the total across 568 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 18.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $2,907 and has fallen 86.8% since, to $383 in 2025.
Across 568 payments — averaging $23.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- AstraZeneca$2K
- Regeneron Healthcare Solutions, Inc.$2K
- Sanofi$1K
- Medtronic$1K
- Biocryst US Sales Co., LLC$868
- plus $4K from 27 others
What the payments were for
- Travel & lodging$1,0788%
- Food & beverage$12,32291%
- Education$1511%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 120 | $2,490 |
| AstraZeneca | 71 | $1,917 |
| Regeneron Healthcare Solutions, Inc. | 65 | $1,809 |
| Sanofi | 48 | $1,187 |
| Medtronic | 2 | $1,120 |
| Biocryst US Sales Co., LLC | 55 | $868 |
| Optinose US, Inc. | 20 | $479 |
| Amgen | 25 | $464 |
| Novartis | 27 | $456 |
| AbbVie | 21 | $355 |
| Boehringer Ingelheim | 12 | $339 |
| Alk-abello, Inc | 9 | $322 |
| Genentech USA, Inc. | 15 | $275 |
| CSL Behring | 13 | $235 |
| Pfizer | 11 | $193 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $191 |
| Aimmune Therapeutics, Inc. | 6 | $106 |
| LEO Pharma Inc. | 6 | $106 |
| Phadia US Inc. | 5 | $100 |
| Blueprint Medicines Corporation | 4 | $96 |
| Pharming Healthcare, Inc. | 5 | $78 |
| Greer Laboratories, Inc. | 3 | $63 |
| USWM, LLC | 2 | $46 |
| Seqirus USA Inc | 2 | $45 |
| Hikma Pharmaceuticals USA | 2 | $35 |
| Teva Pharmaceuticals USA, Inc. | 2 | $31 |
| Inspire Medical Systems, Inc. | 1 | $30 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $25 |
| Octapharma USA, Inc. | 1 | $22 |
| Merck | 1 | $21 |
| Incyte Corporation | 1 | $19 |
| Kaleo, Inc. | 1 | $18 |
| Eisai Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$1,100
- PIVOX Oblique Lateral Spinal System$1,078
- NUCALA$375
- FASENRA$244
- AREXVY$232
- AIRSUPRA$135
- Orladeyo$130
- TEZSPIRE$125
- SYMBICORT$119
- BEVESPI AEROSPHERE$119
- TRELEGY ELLIPTA$116
How this compares
$13,551 in reported general payments places this provider in the 85th percentile of 54 allergy & immunology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 18 | $57,106 |
| XolairOmalizumab | 21 | $50,238 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $42,475 |
| SymbicortBudesonide/Formoterol Fumarate | 44 | $11,303 |
| Qvar RedihalerBeclomethasone Dipropionate | 17 | $8,205 |
| Spiriva RespimatTiotropium Bromide | 13 | $6,742 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $6,245 |
| Advair HfaFluticasone Propion/Salmeterol | 17 | $4,573 |
| Epinephrine | 27 | $3,067 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 15 | $2,919 |
| Fluticasone Propionate HfaFluticasone Propionate | 14 | $2,914 |
| Mometasone Furoate | 16 | $2,321 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 64 | $2,074 |
| Wixela InhubFluticasone Propion/Salmeterol | 25 | $1,891 |
| Montelukast Sodium | 83 | $961 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringHizentra | $235 | $57,10618 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $2,490 | $48,72045 claims |
| AstraZenecaSymbicort | $1,917 | $11,30344 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $31 | $8,20517 claims |
| Boehringer IngelheimSpiriva Respimat | $339 | $6,74213 claims |
| Hikma Pharmaceuticals USAEpinephrine | $35 | $3,06727 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 54 allergy & immunology providers in Connecticut.
Other allergy & immunology in Glastonbury
- Benoit TanoGlastonbury$2K
- Gavin SchwarzWest Hartford$262K
- Christina PriceNew Haven$96K
- Florence HsuNorth Haven$84K
- Jason LeeWest Hartford$30K
- Birur ChandraEast Haven$15K
- Michael KingTrumbull$14K
- Anita Kohli-PamnaniOrange$12K
- Jigisha MoroskyEnfield$12K
- Kenneth BackmanFairfield$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.